On Friday, U.S. Bancorp (NYSE:USB)’s shares declined -0.95% to $40.73.
U.S. Bank has opened an account for donations to the Greater Douglas United Way in Roseburg, Ore., in support of victims of the recent tragedy at Umpqua Community College (UCC). In addition, U.S. Bank has made a $25,000 contribution to the Greater Douglas United Way.
U.S. Bank is the largest bank in Oregon, with three branches in Roseburg. Contributions can be made through any U.S. Bank branch nationwide, under the account name, “Greater Douglas United Way Roseburg UCC Relief Fund.”
U.S. Bancorp, a financial services holding company, provides a range of financial services in the United States. It offers depository services, which comprise checking accounts, savings accounts, and time certificate contracts; and lending services, such as traditional credit products, in addition to credit card services, leasing, financing and import/export trade, asset-backed lending, agricultural finance, and other products.
Penn West Petroleum Ltd (USA) (NYSE:PWE)’s shares gained 20.00% to $0.600.
PENN WEST PETROLEUM LTD. (PWE) declare that it has reached a definitive agreement for the sale of its non-operated 9.5% working interest in the Weyburn Unit in Southeast Saskatchewan for cash consideration of $205 million, subject to closing adjustments customary in transactions of this nature. We intend to use the proceeds from this disposition to reduce our senior debt. Upon the completion of the sale of our Weyburn Unit working interest, we will have raised about $810 million in total proceeds this year through our non-core asset disposition program.
Penn West Petroleum Ltd. explores for, develops, and produces oil and natural gas properties in western Canada. The company’s properties are located in Alberta, British Columbia, Saskatchewan, Manitoba, and the Northwest Territories, Canada; and Wyoming, the United States.
At the end of Friday’s trade, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)‘s shares surged 2.67% to $60.06.
Teva Pharmaceutical Industries Ltd., (TEVA) declared that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b studies of TEV-48125, a monoclonal anti-calcitonin gene-related peptide (CGRP) antibody investigational treatment for the prevention of chronic migraine and high frequency episodic migraine (HFEM). The Lancet Neurology ranks first among 194 journals in the clinical neurology category (2013 Journal Citation Reports®, Thomson Reuters 2014).
The Phase 2b clinical development program consistently met all primary and secondary efficacy and safety endpoints for TEV-48125 in 564 patients and across multiple doses. Clinical improvements were exhibited after a single administration of all tested doses of TEV-48125 in both episodic and chronic migraine studies.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
CVS Health Corp (NYSE:CVS), ended its Friday’s trading session with 2.07% gain, and closed at $98.92.
CVS Health Corporation (CVS) declared that its board of directors has approved a quarterly dividend of $0.35 (35 cents) per share on the corporation’s common stock. The dividend is payable on November 2, 2015, to holders of record on October 22, 2015.
CVS Health Corporation, together with its auxiliaries, provides integrated pharmacy health care services in the United States. The company operates through Pharmacy Services and Retail Pharmacy segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
